SARS‐CoV‐2 Effects on Psychophysical Olfactory Scores: Prospective Study With Evaluation Before and 60‐Days After Infection

Vaira, Luigi Angelo; Lechien, Jérôme R.; Salzano, Giovanni; Maglitto, Fabio; Boscolo‐Rizzo, Paolo; Hopkins, Claire; Riu, Giacomo De

doi:10.1002/ohn.166

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, the 60-day re-evaluation of controls who developed infection in the follow-up period found that although threshold, discrimination and identification scores returned to levels that classified individuals as normosmic, median T values were significantly lower than before infection. 60 This olfactory alteration, although unconscious and therefore not affecting quality of life, can expose patients to environmental dangers.…”

Section: Discussionmentioning

confidence: 99%

Olfactory recovery following omicron variant infection: a psychophysical prospective case–control study with six-month follow up

et al. 2023

Self Cite

View full text Add to dashboard Cite

Objective This study aimed to evaluate the recovery of olfactory function at six months in individuals infected with the coronavirus disease 2019 omicron variant, using psychophysical tests. Methods A prospective case–control study that included severe acute respiratory syndrome coronavirus-2 patients infected in February and March 2022 was conducted. Patients underwent the Sniffin’ Sticks test within 10 days of infection and again after at least 6 months. The olfactory scores were compared with those of a control group. Results In all, 102 patients and 120 controls were enrolled in the study. At baseline, 26 patients (25.5 per cent) self-reported smell loss. The median threshold, discrimination and identification score was 33.6 (interquartile range, 12.5) for the cases and 36.5 (interquartile range, 4.38) for the controls (p < 0.001). Based on the threshold, discrimination and identification scores, 12 controls and 34 patients reported olfactory dysfunction (p < 0.001). Eighty cases underwent re-evaluation at six months; the median threshold, discrimination and identification score was 37.1 (interquartile range, 4.75) with no significant differences compared with the controls. Conclusion Six months after infection, the prevalence of olfactory dysfunction in patients did not differ significantly from the control population.

show abstract

Section: Discussionmentioning

confidence: 99%

Olfactory recovery following omicron variant infection: a psychophysical prospective case–control study with six-month follow up

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Topical platelet‐rich plasma as a possible treatment for olfactory dysfunction—A randomized controlled trial

Duffy,

Naimi,

Garvey

et al. 2024

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

BackgroundOlfactory dysfunction (OD) affects many survivors of COVID‐19. Prior studies have investigated the use of platelet‐rich plasma (PRP) injections for OD. We describe the first randomized controlled trial investigating topical PRP for OD treatment and contribute to existing literature illustrating PRP as an emerging therapeutic.MethodsThis is a single‐blinded, randomized controlled trial conducted from July 2022 to December 2023. Adult patients with OD ≥6 months secondary to COVID‐19 with Brief Smell Identification Test (BSIT) scores of ≤8/12 or SCENTinel odor intensity of ≤40/100 were included. Patients were randomized to three, monthly PRP or placebo‐impregnated Surgifoam treatments into bilateral olfactory clefts. The BSIT, SCENTinel, and Questionnaire of Olfactory Disorders—Negative Statements (QOD‐NS) were completed monthly through month 12.ResultsOf 104 patients screened, 83 participated. No significant differences in age, OD duration, BSIT, SCENTinel, or QOD‐NS scores were found between PRP (n = 42) and placebo (n = 41) patients at baseline. PRP patients experienced a statistically significant increase in BSIT scores from baseline at months 5‒9, 11, and 12, while placebo patients did not (p < 0.05). However, total BSIT scores were similar between the two groups throughout the study. Neither the SCENTinel odor intensity scores nor the change from baseline were significantly different between the treatment groups. At month 12, PRP patients experienced minor improvement in OD‐related quality‐of‐life compared with placebo.ConclusionsThis study is the first to describe topical PRP as a safe, experimental treatment for OD in humans. PRP may impact odor identification in post‐COVID‐19 OD patients, although the lack of difference in total BSIT scores highlights the need for further study.

show abstract

SARS‐CoV‐2 Effects on Psychophysical Olfactory Scores: Prospective Study With Evaluation Before and 60‐Days After Infection

Cited by 2 publications

References 23 publications

Olfactory recovery following omicron variant infection: a psychophysical prospective case–control study with six-month follow up

Olfactory recovery following omicron variant infection: a psychophysical prospective case–control study with six-month follow up

Topical platelet‐rich plasma as a possible treatment for olfactory dysfunction—A randomized controlled trial

Contact Info

Product

Resources

About